戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 s can be an innovative tool in management of retinal vein occlusion.
2 eneration (AMD), diabetic macular edema, and retinal vein occlusion.
3 cular degeneration, diabetic maculopathy, or retinal vein occlusion.
4 eovascularization in the pig model of branch retinal vein occlusion.
5 he treatment of macular edema due to central retinal vein occlusion.
6 cluded from the therapy approval studies for retinal vein occlusion.
7  and treatment of recurrent macular edema in retinal vein occlusion.
8 quantify macular edema in central and branch retinal vein occlusion.
9 improving visual acuity in participants with retinal vein occlusion.
10 efield angiogram images of eyes with central retinal vein occlusion.
11  edema secondary to either central or branch retinal vein occlusion.
12 egeneration or macular edema attributable to retinal vein occlusion.
13 oliferative diabetic retinopathy and central retinal vein occlusion.
14 ge-related macular degeneration, and central retinal vein occlusions.
15 nsive retinopathy 0.88%, macular scar 0.37%, retinal vein occlusion 0.50%, macular hole 0.20%, retini
16 s in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) and to compare with co
17 s in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2).
18 ) in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2); evaluate the baseline
19 ration: 34.2 %; diabetic retinopathy: 4.2 %; retinal vein occlusion: 3.8 %).
20 rtery occlusion (4/16), and isolated central retinal vein occlusion (4/16).
21 ction (5 with central and 2 with hemicentral retinal vein occlusion), 4 eyes were unremarkable at pre
22 tinal artery occlusion and 463 patients with retinal vein occlusion, 66 (58.4%) and 245 (52.9%) were
23  contributor to macular edema resulting from retinal vein occlusion, also confirmed in multicenter tr
24 derived anatomic measurements between branch retinal vein occlusion and central retinal vein occlusio
25 e main are age-related macular degeneration, retinal vein occlusion and diabetic macular edema.
26                     In patients with central retinal vein occlusion and initially low visual acuity,
27 thickness in patients suffering from central retinal vein occlusion and low visual acuity (<0.1) in c
28 sc were made for 13 patients with DE (7 with retinal vein occlusions and 6 with inflammatory optic ne
29 ckings (AVNs) in the retina are the cause of retinal vein occlusions and are also surrogates of cereb
30 ortant implications for the understanding of retinal vein occlusions and of cerebrovascular aging.
31 discussing the prognosis and risk factors of retinal vein occlusions and the treatment options.
32 , diabetic macular edema, central and branch retinal vein occlusion, and miscellaneous causes.
33 , in models of retinal degeneration, central retinal vein occlusion, and oxygen-induced retinopathy.
34  such as proliferative diabetic retinopathy, retinal vein occlusion, and retinal detachment, than in
35 omplication of retinal ischemia in diabetes, retinal vein occlusion, and retinopathy of prematurity.
36 nal diseases including diabetic retinopathy, retinal vein occlusion, and retinopathy of prematurity.
37 erative diabetic retinopathy), 8.3% to treat retinal vein occlusions, and 12.9% for all other uses.
38 sive patient, who developed bilateral branch retinal vein occlusion at 6T, the therapy was discontinu
39 betic macular oedema (DME) or branch/central retinal vein occlusion (B/CRVO).
40  patients with diabetic retinal diseases and retinal vein occlusions (both <0.1 per 1000 retinal vein
41                                           In retinal vein occlusion, both ranibizumab and Ozurdex hav
42 tral retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) causes hypoperfusion, high
43 ral retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) complicated by macular ede
44 olume distensibility in patients with branch retinal vein occlusion (BRVO) in comparison with normal
45  natural history of visual outcome in branch retinal vein occlusion (BRVO) is fundamental to its mana
46                                       Branch retinal vein occlusion (BRVO) is second only to diabetic
47 optic nerve head (ONH) parameters and branch retinal vein occlusion (BRVO) using spectral domain opti
48 venous crossings are risk factors for branch retinal vein occlusion (BRVO), an eye disease in which c
49 ent due to macular edema secondary to branch retinal vein occlusion (BRVO).
50 ative diabetic retinopathy (PDR), and branch retinal vein occlusion (BRVO).
51 nt of macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
52 ection for macular edema secondary to branch retinal vein occlusion (BRVO).
53 ) for macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
54 pth (VCD) and both central (CRVO) and branch retinal vein occlusions (BRVO) using optical low coheren
55 n occlusion [CRVO]) and 17.4 to 19.1 (branch retinal vein occlusion [BRVO]).
56 ab and steroid implants can be considered in retinal vein occlusion, but trials are awaited to determ
57 ration (nAMD), diabetic macular edema (DME), retinal vein occlusion, choroidal neovascularization (CN
58 ular diseases (e.g., diabetic macular edema, retinal vein occlusion, choroidal neovascularization) ha
59 pain score) and similar to patients in other retinal vein occlusion clinical trials.
60 uently developed retinal artery occlusion or retinal vein occlusion compared with patients undergoing
61  the amount of neovascularization induced by retinal vein occlusion, corneal growth factor pellets, a
62 aphy angiography (OCTA) in eyes with central retinal vein occlusion (CRVO) and branch retinal vein oc
63 o review the definition of ischaemic central retinal vein occlusion (CRVO) and stratify the risk of n
64          To determine the outcome of central retinal vein occlusion (CRVO) in pre-existing glaucoma a
65                                      Central retinal vein occlusion (CRVO) or branch retinal vein occ
66 ents with macular edema secondary to central retinal vein occlusion (CRVO) or hemiretinal vein occlus
67 ble to macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlus
68 fty-five patients with a nonischemic central retinal vein occlusion (CRVO) who were randomized to rec
69    To review the clinical picture of central retinal vein occlusion (CRVO), with an emphasis on recen
70 ers a distinctive retinopathy with a central retinal vein occlusion (CRVO)-like appearance.
71  perfused macular edema in eyes with central retinal vein occlusion (CRVO).
72 nch retinal (BRVO), hemi-retinal and central retinal vein occlusion (CRVO).
73 CG) in eyes with the recent onset of central retinal vein occlusion (CRVO).
74 etic macular edema (DME), central and branch retinal vein occlusion (CRVO/BRVO), central serous chori
75 at 6 and 12 months was 15.0 to 16.5 (central retinal vein occlusion [CRVO]) and 17.4 to 19.1 (branch
76 retinopathy, glaucoma, and branch or central retinal vein occlusion diagnosis.
77 ve (2/26), and neovascular following central retinal vein occlusion from amyloidosis (1/26).
78  and the absence of such a difference in the retinal vein occlusion group could be explained by edema
79  = 0.024); however, the same analysis in the retinal vein occlusion group revealed no significant dif
80 en branch retinal vein occlusion and central retinal vein occlusion groups (all P >/= 0.058); therefo
81                                Patients with retinal vein occlusion had higher risks of hemorrhagic s
82  to 28 % of patients presenting with central retinal vein occlusion have a baseline BCVA of less than
83 eneration (HR = 1.29; 95% CI: 1.08-1.54) and retinal vein occlusion (HR = 3.94; 95% CI: 3.11-4.99).
84 r managing complications of ischemic central retinal vein occlusion (iCRVO).
85 ged 18 years with macular edema secondary to retinal vein occlusion in the branch vein occlusion (BRA
86                                              Retinal vein occlusion is a common retinal vascular diso
87      Retinal ischemic damage associated with retinal vein occlusion is exacerbated by fluid extravasa
88 cation of diabetes mellitus, prematurity, or retinal vein occlusion, is a major cause of blindness wo
89                                 In eyes with retinal vein occlusion, longer ME duration at the time o
90 ve of best-corrected visual acuity (BCVA) in retinal vein occlusion macular edema (RVO-ME).
91 g, contralateral PCME, diabetic retinopathy, retinal vein occlusion, macular hole, epiretinal membran
92 pressure in the cat after acute experimental retinal vein occlusion may define the role of intravascu
93 h retinal arterial occlusion (n = 3), branch retinal vein occlusion (n = 1), vitamin A deficiency (n
94 , diarrhoea, myocardial infarction, pyrexia, retinal vein occlusion, n=1 each; placebo: vomiting, whi
95                     Cystoid macular edema in retinal vein occlusion occurred in relation to altered i
96 caused by inflammatory optic neuropathies or retinal vein occlusions on optical coherence tomography
97 , leakage such as macular edema secondary to retinal vein occlusion, or a combination of proliferatio
98      This suggests that prompt treatment for retinal vein occlusion, particularly BRVO, may be associ
99  retinal vein occlusions (both <0.1 per 1000 retinal vein occlusion patients in 2011, 5.6 and 140.2 i
100 CE PATTERN(R) GUIDELINES: New evidence-based Retinal Vein Occlusions Preferred Practice Pattern(R) (P
101                                              RETINAL VEIN OCCLUSIONS PREFERRED PRACTICE PATTERN(R) GU
102 agent ranibizumab in diabetic macular edema, retinal vein occlusion, pseudophakic macular edema, and
103  diverse conditions as diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, exud
104 E (RR 19.5), diabetic retinopathy (RR 13.1), retinal vein occlusion (RR 12.9), macular hole (RR 7.7),
105 .07), uveitis (RR, 2.88; 95% CI, 1.50-5.51), retinal vein occlusion (RR, 4.47; 95% CI, 2.56-5.92), or
106 R), retinopathie of prematurity (ROP) or the retinal vein occlusion (RVO) are caused through a hypoxi
107                  Macular oedema secondary to retinal vein occlusion (RVO) can cause vision loss due t
108  Results of ocular biometric measurements in retinal vein occlusion (RVO) eyes are still inconclusive
109  the prevalence, pattern and risk factors of retinal vein occlusion (RVO) in an elderly population of
110  the treatment of macular edema secondary to retinal vein occlusion (RVO) in treatment-naive patients
111                           PURPOSE OF REVIEW: Retinal vein occlusion (RVO) is a sight-threatening reti
112 ion (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) were evaluated by Pearson c
113 lopathy including diabetic retinopathy (DR), retinal vein occlusion (RVO), and neovascular-age relate
114 ents with diabetic retinopathy (DR), AMD and retinal vein occlusion (RVO), and to identify potential
115 decreased visual acuity (VA) associated with retinal vein occlusion (RVO).
116 genotype, folate and vitamin B12 status, and retinal vein occlusion (RVO).
117  (CLS-TA), in eyes with macular edema due to retinal vein occlusion (RVO).
118 aturity (ROP), diabetic retinopathy (DR) and retinal vein occlusion (RVO).
119 r treatment of macular edema associated with retinal vein occlusion (RVO).
120 ), diabetic macular edema (DME, n = 400), or retinal vein occlusion (RVO, n = 400) acquired with Zeis
121 condary to AMD or Macular Edema Secondary to Retinal Vein Occlusion, Safety Assessment of Intravitrea
122   The Standard of Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study showed that intravi
123  the Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE)-CRVO trial, CRUISE Study,
124  conditions, including diabetic retinopathy, retinal vein occlusion, sickle cell retinopathy, uveitis
125                    The Collaborative Central Retinal Vein Occlusion Study has recently reported infor
126 ercept in Subjects with Macular Edema Due to Retinal Vein Occlusion (TANZANITE) study who received ei
127 2 patients, one each with Eales' disease and retinal vein occlusion the procedure was unsuccessful, n
128 te to progression of retinal nonperfusion in retinal vein occlusion, the same is true in patients wit
129  reference populations and patients in other retinal vein occlusion trials.
130 ORE2) and to compare with cohorts from other retinal vein occlusion trials.
131 mic diseases including diabetic retinopathy, retinal vein occlusion, uveitis, and HIV-related retinit
132                                           In retinal vein occlusion, venous pressures in a segmental
133                                      Central retinal vein occlusion was associated with an overall in
134                                              Retinal vein occlusion was observed in some Cbs(+/-) mou
135 tinal artery occlusion and 463 patients with retinal vein occlusion were enrolled and matched for age
136 two patients with macular edema secondary to retinal vein occlusion were enrolled in the study.
137                In 20 eyes of 10 pigs, branch retinal vein occlusions were created in a standardized m
138                                              Retinal vein occlusions were further divided into branch
139 e patients, 3 with branch and 9 with central retinal vein occlusion, were imaged in 27 sessions with
140 tic neuropathy in contrast to what occurs in retinal vein occlusion, where edema affects all retinal
141 eyes with macular edema secondary to central retinal vein occlusion, which were treated with a dexame
142      Treatment of macular edema secondary to retinal vein occlusion with ranibizumab has been shown t
143 rysm with subretinal hemorrhage (1), central retinal vein occlusion with vitreous hemorrhage (1), and

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top